Jupiter, FL – [January 15th, 2023] – Myosin Therapeutics is honored to announce its selection to present at the prestigious Florida Venture Forum, a premier gathering of the state’s venture capital and private equity professionals. Dr. Pat Griffin, Co-Founder and Member of the Board of Directors at Myosin Therapeutics, will give a presentation focusing on MT-125, the company’s lead compound for the treatment of glioblastoma (GBM).
The Florida Venture Forum is a renowned statewide support organization that helps innovative companies connect with investors, business professionals, and industry experts. Being selected to present at this forum is a significant opportunity for Myosin Therapeutics to showcase its groundbreaking work in oncology and its rapid path to clinical trials.
Dr. Griffin’s presentation will highlight the progress of MT-125, a small molecule with a novel mechanism of action targeting GBM. MT-125 has shown promise as it impedes the rapid growth of tumor cells and prevents their invasion into healthy tissue, offering the potential to prolong overall survival and improve the quality of life for patients with this aggressive brain cancer. This unique approach distinguishes MT-125 within the oncology field.
Myosin Therapeutics’ leadership team has decades of experience in molecular nanomotors and translating cell biology into effective clinical treatments. The company’s platform offers end-to-end solutions from High Throughput Screening (HTS) to target selectivity profiling. Myosin Therapeutics has developed MT-125 into a potent and selective compound ready to advance through clinical development.
“We are thrilled to be selected to present at the Florida Venture Forum,” said Dr. Pat Griffin. “This opportunity allows us to showcase MT-125’s potential as a groundbreaking treatment for glioblastoma.”
About Myosin Therapeutics
Myosin Therapeutics is a Jupiter, FL-based biotechnology company spun out of the Wertheim UF Scripps Institute (formerly Scripps Research, Florida). The company is focused on developing therapies for oncology and central nervous system indications with a platform for targeting molecular nanomotor proteins. Myosin’s lead programs for glioblastoma and stimulant use disorder target non-muscle myosin II motor proteins.
About Florida Venture Forum
The Florida Venture Forum is a statewide support organization for venture capital and private equity professionals. It provides a platform for companies to showcase their innovations and connect with investors, entrepreneurs, and industry leaders, fostering business growth and economic development across the state.
For more information, email contact@myosintherapeutics.com
